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After chemical, biological, or physical damage, growing (i.e. anagen) hair follicles develop abnormalities that are
collectively called hair follicle dystrophy. Comparatively lower follicular damage induces the ‘‘dystrophic anagen’’
response pathway (¼prolonged, dystrophic anagen, followed by severely retarded follicular recovery). More se-
vere follicular damage induces the dystrophic catagen pathway (¼ immediate anagen termination, followed by
a dystrophic, abnormally shortened telogen and maximally fast follicular recovery). In order to recognize these
distinct damage response strategies of the hair follicle in a clinical or histopathological context, we have used the
well-established C57BL/6J mouse model of cyclophosphamide-induced alopecia to deﬁne pragmatic classiﬁcation
criteria for hair follicle dystrophy (e.g., structure and pigmentation of the hair shaft, location, and volume of ectopic
melanin granules, distension of follicular canal, number of TdT-mediated dUTP nick end labeling positive kera-
tinocytes in the hair bulb; neural cell-adhesion molecule immunoreactivity and alkaline phosphatase activity as
markers for the level of damage to the follicular papilla). These classiﬁcation criteria for hair follicle dystrophy are
useful not only in chemotherapy-induced alopecia models, but also in the screening of drug-treated or mutant mice
in a highly standardized, accurate, sensitive, reproducible, easily applicable, and quantiﬁable manner.
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In response to damage, hair follicles undergo two distinct
pathways of dystrophy, which are characterized by specific
morphological abnormalities. These are particularly prom-
inent and clinically highly relevant in the course of chem-
otherapy-induced alopecia (CIA). Decades ago, different
types of alopecias as well as some key parameters for the
recognition of defined stages of chemotherapy-induced hair
follicle dystrophy in mammals were defined (Braun-Falco
and Theisen, 1959; Braun-Falco, 1961, 1966; Zaun, 1964;
Herzberg, 1966; Kostanecki et al, 1966; Homan et al, 1968).
For nearly 40 y, these publications have been the only ref-
erences for the classification of hair follicle dystrophy,
although none of them offers a comprehensive, unified
classification scheme for use in the laboratory. For this rea-
son, we have developed a set of pragmatic classification
criteria for hair follicle dystrophy, using the C57BL/6J mouse
model of cyclophosphamide (CYP)-induced alopecia (Fig 1)
(Paus et al, 1994c, 1996; Slominski et al, 1996; Schilli et al,
1998; Mu¨ller-Ro¨ver et al, 2000; Peters et al, 2001). Studying
this model, we had found that hair follicles undergo two
distinct pathways of dystrophy when they have suffered
chemical damage (here: by cytostatic drugs) (Paus et al,
1994c). These two damage-response pathways are char-
acterized by specific morphological abnormalities, which
eventually lead to hair loss and alopecia (Fig 2). Therefore,
guidelines for the accurate and standardized classification
of chemotherapy-induced hair follicle dystrophy are urgent-
ly needed, not the least in order to assist in the ongoing
quest to combat CIA by the development of more effective
alopecia-protection strategies.
This review complements our earlier guides on the clas-
sification of murine hair follicle development (Paus et al,
1999) and hair follicle cycling (Mu¨ller-Ro¨ver et al, 2001) so as
to provide a standardized approach to the analysis of
murine hair follicle dystrophy. It serves as a useful com-
panion to a similar guide that has recently been published
for the assessment of human hair follicle dystrophy (Whit-
ing, 2003), and should be of particular interest to all re-
searchers that wish to professionally assess hair follicle
damage inflicted by test agents, engineered or spontaneous
mutations and a wide range of diseases. Given the exqui-
site sensitivity of the hair follicle as a ‘‘biological damage
indicator’’ that is negatively affected, e.g. by an enor-
mous number of different clinically widely used drugs (cf.
Litt, 2004) and by numerous mutations (Nakamura et al,
2002)., a professional assessment of hair follicle dystrophy
along the lines indicated here exemplarily for CIA offers a
simple, yet reliable comprehensive and instructive tool for
Abbreviations: AP, alkaline phosphatase; CIA, chemotherapy-
induced alopecia; CTS, connective tissue sheath; CYP,
cyclophosphamide; DP, dermal papilla; IRS, inner root sheath;
NCAM, neural cell-adhesion molecule; ORS, outer root sheath;
TUNEL, TdT-mediated dUTP nick end labeling
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obtaining novel insights into the biological effects of test
agents.
Based on basic histological and ultrastructural studies
on human and rodent CIA (Braun-Falco, 1966; Herzberg,
1966), we have summarized basic as well as more ad-
vanced auxiliary criteria to define the distinct stages of the
dystrophic anagen and the dystrophic catagen pathway
(Figs 3 and 4) which are widely applicable to different
mouse strains and mutants. In essence, this classification
guide can also be utilized for staging the hair follicles of
other hair-bearing animals, even though species-specific
anatomic differences must be taken into account.
Hair follicle cycling in young mice follows a rather precise
timescale (Paus et al, 1999; Mu¨ller-Ro¨ver et al, 2001). Nev-
ertheless, the fine details of hair follicle cycling are depen-
dent on the genetic background (mouse strain), the sex
(e.g., female mice show a prolonged telogen; S. Mu¨ller-
Ro¨ver, unpublished observation) as well as environmental
factors such as time of the year (temperature, light periods)
and nutritional factors. To avoid associated fluctuations, the
present guide is based on the most extensively studied and
best standardized hair research model, the C57BL/6J mod-
els of depilation-induced hair cycling (Chase, 1954; Paus
et al, 1990, 1994a, b; Mu¨ller-Ro¨ver et al, 2001) and CYP-
induced alopecia (Paus et al, 1994c, 1996; Slominski et al,
1996; Schilli et al, 1998; Mu¨ller-Ro¨ver et al, 2000; Peters
et al, 2001; Ohnemus et al, 2004). Briefly, a wax/rosin mix-
ture is applied on the dorsal skin of 7-wk-old mice with all
dorsal skin hair follicles in the resting phase (telogen), as
evidenced by the homogeneously pink back skin color.
Plucking of the wax/rosin mixture removes all hair shafts
and immediately induces anagen development of unparal-
leled homogeneity and synchrony over the entire depilated
back of the mouse (Chase, 1954; Mu¨ller-Ro¨ver et al, 2001).
Nine days after depilation, all depilated hair follicles have
entered the final stage of the growth phase of the hair cycle
(anagen VI). Around day 17 after depilation the follicles
spontaneously start to undergo regression (catagen) to en-
ter the resting phase (telogen) around day 20 after depilation
(Fig 1A) (for further details see Mu¨ller-Ro¨ver et al, 2001).
In order to induce alopecia in this mouse model, 120–150 mg
per kg body weight CYP are given once intraperitoneally at
day 9 after depilation (Fig 1B). Three to seven days later
the skin is harvested for further analysis (Paus et al, 1994c)
(Fig 1B).
In order to avoid terminological confusion, which is often
caused by differences in how selected terms are used in
hair research publications, we recently have summarized
definitions of key terms employed in the context of this re-
view (Mu¨ller-Ro¨ver et al, 2001). Please note that the term
‘‘proximal’’ here refers to those parts of the hair follicle,
which are located close to the subcutaneous muscle layer,
the panniculus carnosus, whereas ‘‘distal’’ refers to those
parts, which are located close to the epidermis.
Figure 1
Experimental design of the C57BL/6 mouse models of depilation-induced haircycling and chemotherapy-induced alopecia. (A) The C57BL/6
mouse model of depilation-induced hair cycling. Schematic representation of key stages of depilation-induced hair follicle cycling in 7-wk-old female
C57BL/6 mice. At day 0 all hair follicles are in the resting stage (telogen). Hair growth is induced by depilating the hairs with a wax/rosin mixture (for
details see Chase, 1954; Paus et al, 1990, 1994a, b). At day 9 after depilation, all follicles are in anagen VI. Around day 16 after depilation, the first
morphological signs of catagen development are detectable. At day 20 after depilation, all follicles have entered telogen again (for details see Chase,
1954; Paus et al, 1994a; Mu¨ller-Ro¨ver et al, 2001). (B) The C57BL/6 mouse model of cyclophosphamide-induced alopecia. Schematic representation
of the experimental setup of cyclophosphamide-induced hair follicle dystrophy. At day 9 after depilation, 120–150 mg per kg body weight
cyclophosphamide was injected intraperitoneally. Three to seven days after depilation the mice were killed by cervical dislocation and the skin was
harvested as described (Mu¨ller-Ro¨ver et al, 2001).
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How to use this guide
This guide describes general principles, i.e. the two possi-
ble damage-response pathways (dystrophic anagen, dys-
trophic catagen) (Fig 2) and lists detailed criteria for precise
staging of chemotherapy-induced hair follicle dystrophy
(Figs 3 and 4). Table I lists auxiliary methods, while Table II
summarizes general indicators of hair follicle dystrophy,
which are illustrated in detail in Fig 3 (four stages of the
dystrophic anagen pathway) and Fig 4 (four stages of the
dystrophic catagen pathway).
In order to illustrate the key parameters for recognizing
the distinct stages of chemotherapy-induced hair follicle
dystrophy, Figs 3 and 4 are structured as follows: the left-
hand column shows computer-generated schematic draw-
ings of the distinct stages of hair follicle dystrophy. The
central column provides a list of basic and auxiliary clas-
sification criteria, which are separated from each other (top:
basic, bottom: auxiliary criteria). The former are recogniz-
able by routine light microscopy, whereas the latter require
additional staining methods. The basic criteria are applica-
ble to all pigmented mouse strains. The auxiliary criteria
require histochemical techniques (i.e. alkaline phosphatase
(AP) staining; Handjiski et al, 1994 and TdT-mediated dUTP
nick end labeling (TUNEL) staining; Lindner et al, 1997) or
immunohistochemistry for the adhesion receptor neuronal
cell-adhesion molecule (NCAM) (Mu¨ller-Ro¨ver et al, 1998).
The right-hand column illustrates the criteria listed in the
central column with three representative photomicrographs.
The lower-case letters used for indicating key parameters
correspond to the lower-case letters in the central column
list. Note that not all parameters are shown in the right-hand
columns.
Criteria for recognizing the distinct stages
of chemotherapy-induced hair follicle
dystrophy
Two specific pathways of chemotherapy-induced hair
follicle dystrophy Several morphological parameters indi-
cate a dystrophic development of hair follicles induced by
chemotherapy (Table II). The parameters that are easiest to
detect are disruptions of melanin accumulation and transfer
such as intrafollicular or perifollicular ectopic melanin gran-
Figure 2
Damage-response pathways of the hair follicle after chemotherapy. Schematic representation of the two different pathways of chemotherapy-
induced hair follicle dystrophy: the dystrophic anagen pathway and the dystrophic catagen pathway. The size of the black flash () indicates how
severely the follicle has been damaged, dependent on the administered dose of the cytostatic agent. In the white boxes, recognized factors are
listed which promote the corresponding pathway, whereas the damage pathways shown here have, so far, only rigorously studied for cyclophosph-
amide-induced alopecia, both in mice and man, they likely apply also to other forms of chemical or biological damage of the hair follicle and the
subsequent follicle response (cf. Braun-Falco and Theisen, 1959; Braun-Falco, 1961; Zaun, 1964; Herzberg, 1966; Whiting, 2003). During the
dystrophic anagen pathway the hair shaft is shed and the follicle undergoes an incomplete primary recovery. The follicle is not fully recovered before
it undergoes a complete catagen–telogen transition to enter the final secondary recovery stage. In contrast, during the dystrophic catagen pathway,
the follicle is more severely damaged and enters directly into dystrophic catagen and a shortened dystrophic telogen. Without passing through a
primary recovery the follicle enters directly into a complete secondary recovery stage. The question mark indicates that it cannot be excluded that
dystrophic anagen might also lead into the dystrophic catagen pathway.
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ules and irregular banding patterns of the hair shaft such as
the disruption of the typical zebra stripe pattern of normal
hair shafts. Other key parameters of hair follicle dystrophy
are a wide-open hair canal, distortion of the entire follicle,
and an irregular diameter of hair follicles. Previous studies
using the C57BL/6 mouse model for CYP-induced alopecia
(Fig 1) revealed two specific pathways of chemotherapy-
induced hair follicle dystrophy (Fig 2) dependent on the se-
verity of the damage (Zaun, 1964; Paus et al, 1994c). These
two different pathways are the ‘‘dystrophic anagen path-
way’’ induced by a lower dose of CYP (120 mg per kg body
weight) (Figs 2 and 3) and the ‘‘dystrophic catagen path-
way’’ induced by a higher dose (150 mg per kg body weight)
of CYP (Figs 2 and 4).
Briefly, the dystrophic anagen pathway is characterized
by a dystrophic anagen development during which the hair
shaft is shed. The dystrophic anagen leads to an incomplete
so-called ‘‘primary recovery’’, during which the hair follicle
regenerates and produces a faulty new hair shaft whose
banding pattern is still slightly disrupted. The subsequent
catagen–telogen transition morphologically appears normal
and is followed by the so-called ‘‘secondary recovery’’,
during which a new anagen follicle with normal pigmenta-
tion and a normal hair shaft banding pattern is generated. In
contrast, the dystrophic catagen pathway is characterized
by immediate entry into a dystrophic catagen without a
‘‘primary recovery’’, followed by a dramatically shortened
and dystrophic telogen leading to a ‘‘secondary recovery’’
(Paus et al, 1994c). In order to accurately quantify the mac-
roscopically visible phenotype changes that accompany
chemotherapy-induced hair loss and hair cycle manipula-
tion, we have recently proposed a simple dot matrix anal-
ysis technique (Ohnemus et al, 2004). This offers an ideal
macroscopial comparison method for correlative and quan-
titative histomorphometry data on hair follicle dystrophy
with the ‘‘clinical’’ results of chemotherapy-induced hair
follicle damage.
Identiﬁcation of the hair cycle stage To distinguish dys-
trophic anagen, catagen and telogen hair follicles, it is nec-
essary to apply first the parameters for the recognition and
staging of normal hair follicles, which have been summa-
rized in the companion guide of the current review (Mu¨ller-
Ro¨ver et al, 2001). Identifying the precise hair cycle stage of
Figure 3
A comprehensive guide for the recognition and classification of distinct stages of dysotropic anagen. The left-hand column shows a
computer-generated schematic drawing of healthy and dystrophic anagen stages and dystrophic catagen and telogen stages. The second column
summarizes essential basic criteria for the recognition of single stages (above dotted line) and auxiliary criteria for more precise staging. The right-
hand column shows representative micrographs of each dystrophy stage (lower-case letters correspond to lower-case letters used in the central
column). The following staining techniques were employed: 3A, D, G, K; 4E, G, J, L: Giemsa-staining technique (Romeis, 1991); 3B, E, H, J; 4A, D, K:
alkaline phosphatase staining (Handjiski et al, 1994); 4B, H: NCAM immunoreactivity (Mu¨ller-Ro¨ver et al, 1998). Please note: upper-case letters in the
left-hand corner label the image whereas lower-case letters identify tissues corresponding to the lower-case letters of the criteria listed in the
central column. Please also note: the left-hand column comprehensively lists all helpful markers, although not all markers are shown in the
micrographs.
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all hair follicles is the first step in determining whether the
majority of follicles is in the dystrophic anagen or the dys-
trophic catagen pathway. It is important to note that dys-
trophy and alopecia develop in a wave from head to tail
(Mu¨ller-Ro¨ver et al, 2000), if the chemotherapeutic agent has
been applied systemically. Thus, hair follicles located in
the same back skin region can be expected to be in a
comparable stage of hair follicle cycling and dystrophy.
However, individual follicles in one region can display very
distinct cycling and dystrophy stages compared with the
majority of their neighboring follicles (Paus et al, 1994c).
This reflects that the interindividual damage response be-
tween hair follicles underlies greater variations than one
would expect from the deceptively similar morphology of
hair follicles at the time of damage initiation. Therefore, it is
important to strictly focus on one well-defined area of the
dorsal skin, e.g. the neck region (cf. Paus et al, 1999) of test
and control mice to avoid artifacts and misleading data
caused by an incorrect skin harvesting method.
Characteristics for recognizing and staging healthy ana-
gen and distinct dystrophic anagen hair follicles In pig-
mented mice such as the C57BL/6J mice, the next step in
staging dystrophic anagen hair follicles is to evaluate the
location (intra- or intercellular; abnormal location, e.g. in
the most proximal hair matrix, the outer root sheath (ORS),
the connective tissue sheath (CTS), or the dermal papilla
Figure 3 Continued
















These methods provide additional help in determining the stage-spe-
cific morphology of distinct hair follicle compartments such as the dermal
papilla or the trailing connective tissue sheath.
ORS, outer root sheath; IRS, inner root sheath; TUNEL, TdT-mediated
dUTP nick end labeling; NCAM, neural cell-adhesion molecule; CTS,
connective tissue sheath.
Table II. General signs of chemotherapy-induced hair
follicle dystrophy
Ectopic melanin (intrafollicular, perifollicular)
Irregular banding pattern of the hair shaft, fragmented hair shaft
Wide-open hair canal
Follicular distortion, hair shaft distortion
Irregular diameter of hair bulbs
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(DP)) and size of ectopic melanin granules or clumps, com-
pared with the size of keratinocyte nuclei, the integrity of
melanogenesis in the hair follicle pigmentary unit and its
melanin transfer to keratinocytes in the precortical matrix
area, the integrity of the hair shaft (continuous or fragment-
ed hair shaft) and its pigmentation, the number of mitotic
and apoptotic figures, the size of the hair bulb compared
with the size of the DP and the width of the hair canal lumen.
The most easily detectable and probably also most sen-
sitive of these parameters is the location and the size of
ectopic melanin granules or clumps, compared with the size
of keratinocyte nuclei (Slominski et al, 1996; Tobin and
Paus, 2001). In healthy anagen VI hair follicles no ectopic
melanin can be detected in the bulb (Figs 3A,B) (Tobin and
Paus, 2001). In early dystrophic anagen hair follicles ectopic
melanin granules, which are smaller than keratinocyte nu-
clei, can be found in the bulb area (Figs 3D,E). Mid-dys-
trophic anagen follicles are characterized by bigger melanin
clumps, which have the size of keratinocyte nuclei (Figs
3G,H, inset in Fig 3I), whereas late dystrophic anagen fol-
licles display melanin clumps, which are bigger than kera-
tinocyte nuclei (Figs 3J,K).
The integrity of the melanin transfer in the precortical
matrix area is also easy to determine. In healthy and early
dystrophic anagen follicles the melanogenic area of the fol-
licle surrounds the distal pole of the DP like an inverted ‘‘Y’’
(see inset in Fig 3C). During mid-dystrophic anagen, the ‘‘Y’’
shape is smaller, i.e. melanogenesis is reduced but still in-
tact (Figs 3G,H), whereas during late dystrophic anagen the
precortical matrix is asymmetric and no longer ‘‘Y’’ shaped
(Figs 3J,K). The integrity of the hair shaft and its typical
zebra stripe banding pattern is maintained until mid-dys-
trophic anagen (Fig 3H). Only late dystrophic anagen folli-
cles display hair shaft fragments and a loss of the zebra
stripe banding pattern (Fig 3J). In healthy anagen VI hair
follicles, multiple mitotic figures can be detected (Fig 3A),
whereas apoptotic figures are extremely rare. If more
precise quantification is desired, quantitative Ki67
immunohistomorphometry offers a simple and accurate
auxiliary parameter (Table I). The number of apoptotic fig-
ures increases from early dystrophic anagen (more than
three apoptotic figures) (Fig 3E) to late dystrophic anagen
(more than 10 apoptotic figures). Because some experience
is needed to evaluate the number of apoptotic cells and/or
Figure 4
A comprehensive guide for the recognition and classification of distinct stages dystrophic catagen and telogen. The left-hand column shows
a computer-generated schematic drawing of healthy and dystrophic anagen stages and dystrophic catagen and telogen stages. The second column
summarizes essential basic criteria for the recognition of single stages (above dotted line) and auxiliary criteria for more precise staging. The right-
hand column shows representative micrographs of each dystrophy stage (lower-case letters correspond to lower-case letters used in the central
column). The following staining techniques were employed: 3A, D, G, K; 4E, G, J, L: Giemsa-staining technique (Romeis, 1991); 3B, E, H, J; 4A, D, K:
alkaline phosphatase staining (Handjiski et al, 1994); 4B, H: NCAM immunoreactivity (Mu¨ller-Ro¨ver et al, 1998). Please note: upper-case letters in
the left-hand corner label the image whereas lower-case letters identify tissues corresponding to the lower-case letters of the criteria listed in the
central column. Please also note: the left-hand column comprehensively lists all helpful markers, although not all markers are shown in the
micrographs.
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apoptotic bodies, TUNEL reactivity is a reasonable, yet not
entirely reliable marker of apoptosis but a very helpful aux-
iliary method for easily quantifying the number of apoptotic
cells in the hair bulb. In healthy anagen VI hair follicles,
essentially no TUNELþ keratinocytes are found (Fig 3C),
whereas more than three TUNELþ keratinocytes can be
detected in dystrophic anagen hair follicles (Fig 3F), more
than five TUNELþ cells in the bulb region in mid-dystrophic
anagen hair follicles (Fig 3I), and more than 10 TUNELþ
keratinocytes in late dystrophic anagen follicles (Fig 3L). But
one must keep in mind the percentage of TUNELþ cells in
the hair matrix steeply increases with the onset of normal
catagen (Lindner et al, 1997).
When drawing conclusions from these TUNEL data on
the exact features of interfollicular apoptosis in the exper-
iment at hand, caution is advised, because even in the ab-
sence of TUNELþ cells in murine hair follicles, substantial
apoptosis can still be detectable by electronmicroscopy,
and terminally differentiating cells, especially in the inner
root sheath (IRS), often are TUNELþ (Magerl et al, 2001).
Therefore, definitive statements on intrafollicular apoptosis
require ultrastructural confirmation.
Another important parameter is the bulb size compared
with the size of the DP as well as the shape of the DP, which
can be easily visualized by AP staining. The DP of mid-
dystrophic anagen hair follicles becomes oval (Figs 3G,H) in
contrast to the spindle-like DP of early dystrophic anagen
hair follicles. But the DP diameter is still not more than 1/3 of
the bulb diameter (Figs 3G,H), in contrast to the swollen DP
during late dystrophic anagen with a diameter bigger than
1/3 of the bulb diameter (Figs 3G,H).
Finally, the last parameter is the size of the hair canal,
which is slightly widened (Fig 3J) and often filled with hair
shaft fragments during late dystrophic anagen.
Criteria for recognizing and staging dystrophic catagen
and dystrophic telogen hair follicles For staging dys-
trophic catagen and telogen hair follicles, it is essential to
first identify the characteristics of catagen and telogen
follicles by applying the stage-specific parameters des-
cribed previously for healthy catagen and telogen hair
follicles (Mu¨ller-Ro¨ver et al, 2001). For greater simplicity,
catagen stages I–III are defined as ‘‘early catagen’’, catagen
stages IV to V are defined as ‘‘mid-catagen’’, catagen stag-
es VI–VIII are defined as ‘‘late catagen’’ (Straile et al, 1961;
Parakkal, 1970). Briefly, the key parameters for staging are
the length of the follicle as well as the shape and location of
the DP (in the subcutis during early and mid-dystrophic
catagen (Figs 4A,H), close to the border between dermis
and subcutis during late dystrophic catagen and telogen
(Figs 4G,H, J,K)) and the presence of a trailing, NCAMþ
CTS tail proximal to the DP during late dystrophic catagen
(Fig 4H). In addition to the phase-specific staging, it is nec-
essary to distinguish these follicles from healthy catagen
and telogen hair follicles. In contrast to healthy catagen,
normal club hair formation is not observed at any time dur-
Figure 4 Continued
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ing any dystrophic catagen, and only hair shaft fragments
are visible in the hair canal (Figs 4A–I). Furthermore, sub-
stantial follicular distortion (characterized by a wave-like
basement membrane; Fig 4E) and an abnormal widening of
the hair canal are detectable (Figs 4A,D). Finally, ectopic
melanin clumps that are, for the most part, larger than ker-
atinocyte nuclei can be found in the IRS, ORS, and CTS of
all dystrophic catagen and telogen follicles (Fig 4). NCAM
immunohistochemistry as an auxiliary method helps to vis-
ualize the proximal CTS during early and mid-dystrophic
catagen as well as the trailing CTS tail during late dystrophic
catagen (Fig 4H). AP staining greatly aids in locating of the
DP and visualizing its exact shape, which is onion-like dur-
ing early dystrophic catagen and ball shaped in all consec-
Table III. Examples of previous studies on CIA in mice that have employed the suggested criteria for classifying hair
follicle dystrophy
Reference Key ﬁndings
Paus et al (1994c) Identification of the basic HF response to chemotherapy (CYP): ‘‘primary recovery’’, ‘‘secondary recovery’’,
‘‘dystophic anagen’’, ‘‘dystrophic catagen’’; cyclosporine A shifts the HF response to CYP toward a mild
form of dystrophic anagen, thus retarding CIA and prolonging ‘‘primary recovery’’. Topical dexamethasone,
in contrast, forces HF into dystrophic catagen, which augments CIA, but accelerates the regrowth of normally
pigmented hair (‘‘secondary recovery’’). Identification of abnormalities in the hair follicle pigmentary unit as a
particularly sensitive marker for hair follicle damage
Slominski et al (1996) CYP disrupts of follicular melanogenesis (significant alterations of biochemical and biophysical markers of
melanogenesis, incl. tyrosine hydroxylase activity of tyrosinase and dihydroxyphenylalanine oxidation,
DOPAchrome tautomerase activity). Tyrosinase is the most sensitive target of the melanogenic apparatus for
pharmacological regulation. Follicle pigmentation recovers only after a new anagen hair bulb has been
constructed, which points to the existence of a relatively chemoresistant melanoblast-like cell population residing
in the non-cycling part of the hair follicle
Paus et al (1996) Calcitriol administration to CYP-treated mice favors the ‘‘dystrophic catagen pathway’’, thus enhancing the
regrowth of a normal hair coat
Maurer et al (1997) Topical cyclosporine A and FK 506 provide relative protection from CYP-induced CIA and HF dystrophy by
favoring the dystrophic anagen pathway
Lindner et al (1997) During CYP-induced HF dystrophy and CIA, massive keratinocyte apoptosis occurs in the entire proximal hair
bulb epithelium, except in the dermal papilla
Lindner et al (1997) Treatment of mice with IL-15-IgG fusion protein mitigates CYP-induced HF dystrophy
Schilli et al (1998) Calcitriol reduces HF keratinocyte apoptosis in CYP-treated HF
Tobin et al (1998) CYP-induced dystrophic catagen initially shows retention of melanogenic and dendritic melanocytes despite
the presence of widespread keratinocyte apoptosis. This is followed by melanocyte incontinence, the ectopic
distribution of melanin, and at least partial apoptosis of melanocytes in the CYP-damaged HF pigmentary unit.
Interesting in situ model for studying the melanocyte response to chemical
Botchkarev et al (2000) p53 is an essential factor for HF dystrophy in CYP-induced CIA: In contrast to wild-type controls, p53-deficient
mice show neither hair loss nor apoptosis in the HF keratinocytes, which even maintain their proliferative active
after CYP treatment
Mu¨ller-Ro¨ver et al (2000) In contrast, and different from what would have been expected, transgenic mice that overexpress human Bcl-2 in
the outer root sheath under the control of the human keratin-14 promoter (K14/Bcl-2), show more signs of
CYP-induced HF dystrophy and keratinocyte apoptosis that WT controls
Peters et al (2001) Parathyroid hormone-related peptide (PTHrP) and the PTH/PTHrP receptor (PTH/PTHrP-R) may exert important
paracrine and/or autocrine functions in hair growth control. The PTH/PTHrP-R agonist PTH(1–34) forces HF into
dystrophic catagen, associated with enhanced intrafollicular apoptosis, whereas the antagonists PTH(7–34) and
PTHrP(7–34) shift the HF response to CYP toward a mild form of dystrophic anagen, associated with a significant
reduction in apoptotic hair bulb cells, thus mitigating the degree of follicle damage and retarding the onset of CIA.
PTH/PTHrP-R agonists and antagonists may have promise for managing CIA in humans
Sharov et al (2003) CYP administration to C57BL/6 mice induces a complex response in HF melanocytes, which includes apoptosis,
proliferation, and migration: Hair bulb melanocytes expressing Fas undergo apoptosis, whereas CYP-treated Fas
knockout mice show much fewer apoptotic HF melanocytes. Surviving hair bulb melanocytes express c-kit
receptor, proliferate, and appear to migrate up the outer root sheath. Tyrosinase-positive and melanogenically
active cells then appear in the epidermis. Expression levels of the c-kit ligand, stem cell factor, in skin and
epidermis are strongly increased after CYP treatment. CYP-induced migration of HF melanocytes to the
epidermis is abrogated by c-kit neutralizing antibody. Pharmacologic manipulation of Fas and c-kit signaling
pathways might be useful for the correcting the skin hyperpigmentation that can occur as a side-effect of
chemotherapy
Sharov et al (2004) As a p53 target, Fas plays important role in the HF response to CYP: Fas is upregulated in HF keratinocytes after
CYP treatment, Fas ligand-neutralizing antibody partially inhibits HF dystrophy, and Fas knockout mice show
retarded dystrophic catagen, associated with reduced Fas-associated death domain and caspase-8 expression
Ohnemus et al (2004) Topical 17-b-estradiol forces CYP-damaged HF into the dystrophic catagen response pathway, with a subsequent
acceleration of the regrowth of normally pigmented hair shafts
CYP, cyclophosphamide; CIA, chemotherapy-induced alopecia.
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utive stages (Figs 4A–C). The TUNEL-staining method helps
to detect the high number of apoptotic keratinocytes in the
bulb and epithelial strand of dystrophic catagen and telogen
follicles (Figs 4F, I, L). Notably, even in the face of massive
chemotherapeutic damage, the DP does not show
TUNELþ fibroblasts (Lindner et al, 1997; Tobin et al,
2003) indicating that DP cells are highly apoptosis-resist-
ant in situ. Therefore, if TUNELþ cells should ever be noted
in the DP in a given experimental setup, this is a particularly
interesting feature, which must be followed-up carefully.
Early dystrophic catagen hair follicles are characterized
by a follicular distortion, which can be easily detected light
microscopically because of the wave-like shape of the
basement membrane (Figs 4A,B). The DP is condensed
and onion-or ball-shaped (Figs 4A–C), in contrast to the
spindle like or swollen appearance of healthy or dystrophic
anagen hair follicles. A small CTS tail proximal to the DP
can be easily visualized by NCAM immunohistochemistry
(Fig 4B). Melanin clumps bigger than keratinocyte nuclei
can be found in IRS, ORS, and the regressing bulb as well
as in the proximal CTS (Figs 4A–C). The bulb is reduced
in size (Figs 4A–C) and more than 10 apoptotic figures
and TUNELþ cells, respectively, are present (not shown).
The hair canal is widened and filled with hair shaft remnants
(Fig 4A).
Distinguishing early and mid-dystrophic catagen is only
possible by comparison with the stage-specific parameters
of healthy follicles in early and mid-catagen (Mu¨ller-Ro¨ver
et al, 2001). The DP is now condensed and ball shaped, it is
located in the middle of the subcutaneous fat layer because
the follicle is shorter and it is no longer fully surrounded by
bulb keratinocytes (Figs 4D,E). The CTS proximal to the DP
is elongated, which is not easily detectable by light micros-
copy (Fig 4E) but can be nicely visualized by NCAM
immunoreactivity (not shown). In contrast to healthy cata-
gen, no club hair is formed and in contrast to late dystrophic
catagen, there is still no trailing CTS tail (Fig 4E).
Late dystrophic catagen is the easiest stage to be rec-
ognized, because the trailing CTS tail is filled with large
melanin clumps and is intensively marked by NCAM histo-
chemistry (Fig 4). In addition, the follicle is much shorter
than dystrophic anagen and earlier dystrophic catagen fol-
licles. The DP is now localized close to the border between
subcutis and dermis (Figs 4G,H). Experienced researchers
will be able to localize the condensed, ball-shaped DP in the
melanin-filled trailing CTS tail. Melanin clumps are present
in the regressing epithelial strand (between the DP and
secondary hair germ) and in the CTS (Figs 4G,H). Remnants
of the hair shaft can be found in the widened hair canal (Figs
4G,H). In the epithelial strand multiple TUNELþ cells are
present (Fig 4I).
Three parameters help to distinguish dystrophic telogen
from late dystrophic catagen: dystrophic telogen follicles
are shorter and the ball-shaped DP resides mainly in the
dermis and is mostly surrounded by dermal fibroblasts (Figs
4J–L). In addition, there is no NCAMþ CTS tail trailing
proximal to the DP (not shown). Similar to earlier stages,
melanin clumps are present around the DP, in the germ
capsule and in the perifollicular CTS (Figs 4J–L). The hair
canal is abnormally wide open and no club hair is present
(Figs 4J,K).
Analysis of hair follicle dystrophy in
pharmacologically treated or mutant mice
Using the qualitative criteria characterized in this review, it is
possible to make fully quantitative comparisons of hair fol-
licle dystrophy not only in CYP treated, but also in a wide
range of pharmacologically treated, biologically manipulat-
ed, and mutant mice, compared with age-matched wild
type or appropriate vehicle controls. For quantitative ex-
periments, a sufficiently large number of age- and sex-
matched test and control mice should be compared by
quantitative histomorphometry, i.e. the morphological crite-
ria described above should be used to determine the stages
of a defined number of longitudinally cut hair follicles per
mouse (e.g. 420 hair follicles per mouse, studying at least
three to five mice per time point and group). Quantitative
histomorphometry for the study of abnormalities during one
of the two pathways of hair follicle dystrophy, using the
classification criteria suggested here, has been used in
several of our previous publications, which may be con-
sulted for examples. Table III lists examples of previous
studies on CIA in mice that have employed the suggested
criteria for classifying hair follicle dystrophy and summarizes
the basic findings.
For the qualitative and quantitative evaluation of hair fol-
licle dystrophy it is of pivotal importance to study stand-
ardized longitudinal sections of hair follicles prepared by
using a special harvesting and embedding technique (Paus
et al, 1999). A sufficient number of well-cut skin sections
has to be prepared for each mouse in order to attribute the
hair follicle to defined dystrophy stages. The total number of
hair follicles per dystrophy stage can be then compared
quantitatively and statistically between test and control
mice.
This quantitative approach can be further elaborated by
calculating a ‘‘dystrophy score’’. This allows a quantitative
comparison of the development of hair follicle dystrophy at
various stages in large hair follicle populations between
test and control groups of mice. To this end, every stage of
dystrophic anagen or catagen is assigned a factor in
ascending numerical order: healthy anagen¼ factor 0, early
dystrophic anagen¼ factor 1, mid-dystrophic anagen¼ fac-
tor 2, late dystrophic anagen¼ factor 3, early dystrophic
catagen¼ factor 4, mid-dystrophic catagen¼ factor 5, late
dystrophic catagen¼ factor 6, dystrophic telogen¼ factor
7. The number of hair follicles in each specific stage is
multiplied by the corresponding factor. The results of each
sum are totalled and divided by the overall number of hair
follicles counted. This gives a final value between 0 and 7,
thus defining the average stage of all hair follicles within the
entire group. This enables the identification of even discrete
abnormalities in the dynamics of hair follicle dystrophy be-
tween test and control mice that might otherwise escape
notice.
In summary, this review offers a comprehensive, prag-
matic, but simple guide to recognizing the morphological
features of murine chemotherapy-induced HF dystrophy,
thus serving as a useful tool for rapid and instructive anal-
yses of murine skin after pharmacological or genetic ma-
nipulations. The schematic drawings of individual dystrophy
stages presented here may be employed by other investi-
50 HENDRIX ET AL THE JOURNAL OF INVESTIGATIVE DERMATOLOGY
gators for reporting the follicular expression patterns of their
genes and proteins of interest so that the documentation
of such expression patterns will provide a framework for
standardized and highly reproducible comparison. In addi-
tion, if combined with an excellent similar guide to the
analysis of human hair follicle dystrophy (Whiting, 2003),
many of the classification criteria listed here for the murine
system can also be employed beneficially when assessing
human hair follicle dystrophy.
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